A Proof-of-Principle Clinical Trial of Bexarotene in Patients with Non–Small Cell Lung Cancer

@article{Dragnev2007APC,
  title={A Proof-of-Principle Clinical Trial of Bexarotene in Patients with Non–Small Cell Lung Cancer},
  author={Konstantin H. Dragnev and W. Jeffrey Petty and Sumit J. Shah and Lionel D. Lewis and Candice C Black and Vincent A. Memoli and William C. Nugent and Thomas W. Hermann and Andrés Negro-Vilar and James R Rigas and Ethan Dmitrovsky},
  journal={Clinical Cancer Research},
  year={2007},
  volume={13},
  pages={1794 - 1800}
}
Purpose: Bexarotene is a rexinoid (selective retinoid X receptor agonist) that affects proliferation, differentiation, and apoptosis in preclinical studies. The relationship between bexarotene levels and biomarker changes in tumor tissues has not been previously studied. Experimental Design: BEAS-2B human bronchial epithelial (HBE) cells, retinoid-resistant BEAS-2B-R1 cells, A427, H226, and H358 lung cancer cells were treated with bexarotene. Proliferation and biomarker expression were assessed… 

Figures and Tables from this paper

Emerging roles of bexarotene in the prevention, treatment and anti-drug resistance of cancers

Bexarotene is an active and reasonable chemoprevention and treatment for various cancers and its combination regimen with other cytotoxic agents or targeted drugs may significantly enhance efficacy and at the same time reduce toxicity due to their nonoverlapping side effects.

Bexarotene via CBP/p300 Induces Suppression of NF-κB–Dependent Cell Growth and Invasion in Thyroid Cancer

Dual mechanisms by which retinoids and rexinoids may target cell tumorigenicity, not only via RARs and RXRs, as expected, but also via NF-κB pathway are highlighted.

Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief report

Bexarotene appears to lower the C max and AUC0–24 of gefitinib through cytochrome P450 CYP3A4, which has pharmacokinetic implications for ongoing trials that combine bexarotenes with other small molecules in the era of personalized cancer therapy.

Bexarotene Plus Erlotinib Suppress Lung Carcinogenesis Independent of KRAS Mutations in Two Clinical Trials and Transgenic Models

The rexinoid bexarotene plus erlotinib was active in KRAS-driven lung cancer cells, was biologically active in early-stage mutant KRAS NSCLC, and was clinically active in advanced, chemotherapy-refractory mutantKRAS tumors in this study and previous trials.

Cellular retinol binding protein 1 transfection reduces proliferation and AKT-related gene expression in H460 non-small lung cancer cells

Investigation of the effect of Cellular retinol binding protein-1 (CRBP-1) transfection in H460 human NSCLC cell line found reduced proliferation and viability in both basal condition and after atRA treatment, likely by down-regulating AKT-related gene level.

Synergistic effect of a retinoid X receptor-selective ligand bexarotene and docetaxel in prostate cancer

Results from this study showed that BEX-induced G2 arrest and DTX-induced mitotic arrest probably contributed to the synergistic effect of BEX andDTX.

Combination of bexarotene and the retinoid CD1530 reduces murine oral-cavity carcinogenesis induced by the carcinogen 4-nitroquinoline 1-oxide

The combination of the drugs bexarotene and CD1530 was more effective than either drug alone in preventing oral carcinogenesis in the authors' mouse model of human oral and esophageal cancers.

Alterations in Retinoic Acid Receptors in Non-Small Cell Lung Cancer and Their Clinical Implications

There is evidence that retinoids have different effects on lung cancer; still the identification of biomarkers could determinate their benefits as preventive or therapy agents.

ANew Rexinoid , NRX 194204 , Prevents Carcinogenesis in Both the Lung andMammary Gland

The combined anti-inflammatory and anticarcinogenic actions of 4204 suggest that it is a promising new rexinoid that should be considered for future clinical trials.

Comparing Histone Deacetylase Inhibitor Responses in Genetically Engineered Mouse Lung Cancer Models and a Window of Opportunity Trial in Patients with Lung Cancer

Combining murine and human HDACi trials is a strategy to translate preclinical HDaci treatment outcomes into the clinic and uncovered clinically tractable mechanisms to engage in future HDAC i trials.
...

References

SHOWING 1-10 OF 36 REFERENCES

Microarray gene expression analysis reveals molecular activities of bexarotene in in vitro models of non-dmall vell lung cancer (NSCLC) and in tumors of NSCLC patients

All cell lines and primary tumor cultures showed changes in gene expression in response to bexarotene to various degrees, indicating a universal capacity of beXarotenes to elicit a molecular response in NSCLC.

Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene.

Bexarotene in combination with chemotherapeutic agents has demonstrated an encouraging median survival for patients with advanced non-small cell lung cancer compared with historical results with combination chemotherapy alone.

Bexarotene and erlotinib for aerodigestive tract cancer.

Combining erlotinib with bexarotene enhanced growth suppression in vitro compared with each single-agent treatment, and these findings are encouraging and warrant further investigation of this regimen.

Optimizing bexarotene therapy for cutaneous T-cell lymphoma.

  • S. E. Whitmore
  • Medicine
    Journal of the American Academy of Dermatology
  • 2004

Optimizing bexarotene therapy for cutaneous T-cell lymphoma.

This single-center study supports the safety and efficacy of bexarotene as both a monotherapy and a combination therapy for CTCL and suggests long durable CRs may be achieved with oral monotherapy.

Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies.

In the intent-to-treat population, bexarotene given as third or subsequent line of therapy for relapsed NSCLC did not achieve the intended median survival of 6 months and may have been extended in patients who developed bexARotene-induced hypertriglyceremia and/or skin rash.

A randomized phase III trial comparing bexarotene/carboplatin/paclitaxel versus carboplatin/paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC)

This randomized, prospective Phase III trial was performed to determine the survival benefit of adding bexarotene to carboplatin/paclitaxel chemotherapy in patients with advanced NSCLC.

Evidence for the epidermal growth factor receptor as a target for lung cancer prevention.

Findings indicate how effective chemoprevention prevents carcinogenic transformation of bronchial epithelial cells when repair of genomic damage does not select against EGFR overexpressing cells.

Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.

  • M. DuvicK. Hymes R. Yocum
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2001
Bexarotene is orally administered, safe, and generally well tolerated with reversible side effects, and is effective for the treatment of advanced, refractory CTCL.

Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer.

  • F. KhuriJ. Rigas W. Hong
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2001
In patients with advanced NSCLC, bexarotene with cisplatin and vinorelbine yielded acceptable phase II response rates (25%) and was associated with better-than-expected survival (14-month median survival time); the regimen should be studied in larger clinical trials.